C. Abdeddaim

发表

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

I. Treilleux, I. Ray-Coquard, V. Marcel, 2022, JAMA oncology.

Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.

D. Berton, D. Spaeth, I. Ray-Coquard, 2022, Gynecologic oncology.

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

D. Berton, G. Curigliano, S. Ellard, 2021 .

733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study

O. Trédan, A. Leary, A. Floquet, 2021, Annals of Oncology.

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

A. Tinker, Jubilee Brown, Susana Banerjee, 2020, JAMA oncology.

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).

I. Treilleux, I. Ray-Coquard, O. Trédan, 2021, Gynecologic oncology.

Abstract CT005: Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial

D. Maucort-Boulch, A. Leary, P. Follana, 2022, Cancer Research.

Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.

F. Clatot, E. Vauléon, Alison C Johnson, 2021, European journal of cancer.

Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.

D. Berton, G. Curigliano, S. Cresta, 2021 .

Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery☆

D. Hudry, F. Narducci, H. El Hajj, 2021, ESMO open.

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

I. Treilleux, E. Kalbacher, A. Floquet, 2020, Gynecologic oncology.

PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.

D. Berton, I. Ray-Coquard, M. Moubarak, 2023, Gynecologic oncology.

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction

D. Hudry, F. Narducci, M. Le Deley, 2021, Cancers.

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.

A. Tinker, Jubilee Brown, Susana Banerjee, 2021, Future oncology.

The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer

Y. Gidron, N. Penel, J. Lequesne, 2022, Frontiers in Oncology.

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

D. Berton, S. Ellard, H. Arkenau, 2023, JAMA network open.